Taken together, this study suggests that enhancing SIK1 activity with ZQR would be expected to decrease hyperglycemia and hyperlipidemia as well as hepatic lipid storage in patients with diabetes with NAFLD. This evidence concerns the gene SIK1 and metabolic dysfunction-associated steatotic liver disease.